EMA/PE/0000226088

CAT quarterly highlights and approved ATMPs - March 2026

Opinion/decision on a Paediatric investigation plan (PIP): Natpar, recombinant parathyroid hormone, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Endocrine disorders, PIP number: EMA/PE/0000225073

Opinion/decision on a Paediatric investigation plan (PIP): Epidyolex, cannabidiol, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: EMA/PE/0000224912

EMA/PE/0000224955

EMA/PE/0000224883

EMA/PE/0000225023

EMA/PE/0000225241

Opinion/decision on a Paediatric investigation plan (PIP): Voxzogo, vosoritide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: EMA/PE/0000224768

Opinion/decision on a Paediatric investigation plan (PIP): Reagila, cariprazine hydrochloride, decision type: RPM: decision refers to a refusal on the application for modification of an agreed PIP, therapeutic area: Psychiatric disorders, PIP number: EMA/PE/0000224597